Broadening eligibility criteria to make clinical trials more representative: American society of clinical oncology and friends of cancer research joint research statement

Journal of Clinical Oncology

Volumn 35, Issue 33, 2017, Pages 3737-3744

  Kim, Edward S ^a   Bruinooge, Suanna S ^b   Roberts, Samantha ^c,d   Ison, Gwynn ^e   Lin, Nancy U ^g   Gore, Lia ⁱ   Uldrick, Thomas S ^f   Lichtman, Stuart M ^j   Roach, Nancy ^k   Beaver, Julia A ^e   Sridhara, Rajeshwari ^e   Hesketh, Paul J ^h   Denicoff, Andrea M ^f   Garrett Mayer, Elizabeth ^l   Rubin, Eric ^m   Multani, Pratik ⁿ   Prowell, Tatiana M ^e   Schenkel, Caroline ^b   Kozak, Marina ^c   Allen, Jeff ^c   Sigal, Ellen ^c   Schilsky, Richard L ^b   more..

^a Levine Cancer Institute   (United States)

^b ASCO   (United States)

^c Friends of Cancer Research   (United States)

^d GENENTECH INC   (United States)

^e CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^f NATIONAL CANCER INSTITUTE   (United States)

^g DANA FARBER CANCER INSTITUTE   (United States)

^h Lahey Health Cancer Institute   (United States)

ⁱ UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^j MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^k Fight Colorectal Cancer (Fight CRC)   (United States)

^l MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^m MERCK RESEARCH LABORATORIES   (United States)

ⁿ Ignyta   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN;

AGE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BRAIN METASTASIS; CLINICAL TRIAL (TOPIC); CONSENSUS; CREATININE CLEARANCE; ELECTROCARDIOGRAPHY MONITORING; EXPERIMENTAL THERAPY; HEART DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; LIVER DYSFUNCTION; LIVER FUNCTION; LOW RISK POPULATION; MEDICAL SOCIETY; NEW YORK HEART ASSOCIATION CLASS; PATIENT SAFETY; PATIENT SELECTION; PRIORITY JOURNAL; URINARY EXCRETION; EARLY CANCER DIAGNOSIS; MEDICAL RESEARCH; ONCOLOGY; ORGANIZATION AND MANAGEMENT; PROCEDURES; UNITED STATES;

BIOMEDICAL RESEARCH; CLINICAL TRIALS AS TOPIC; EARLY DETECTION OF CANCER; ELIGIBILITY DETERMINATION; HUMANS; MEDICAL ONCOLOGY; UNITED STATES;

EID: 85034427766     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2017.73.7916     Document Type: Article

References (30)

1. Siu LL, Tannock IF: Problems in interpreting clinical trials, in Crowley J (ed): Handbook of Statistics in Clinical Oncology. New York, NY, Marcel Dekker, 2001, pp 473-491
2. George SL: Reducing patient eligibility criteria in cancer clinical trials. J Clin Oncol 14:1364-1370, 1996
3. Fuks A, Weijer C, Freedman B, et al: A study in contrasts: Eligibility criteria in a twenty-year sample of NSABP and POG clinical trials. J Clin Epidemiol 51: 69-79, 1998
4. Kim ES, Bernstein D, Hilsenbeck SG, et al: Modernizing eligibility criteria for molecularly driven trials. J Clin Oncol 33:2815-2820, 2015
5. Beaver JA, Ison G, Pazdur R: Reevaluating eligibility criteria: Balancing patient protection and participation in oncology trials. N Engl J Med 376: 1504-1505, 2017
6. Fehrenbacher L, Ackerson L, Somkin C: Randomized clinical trial eligibility rates for chemotherapy (CT) and antiangiogenic therapy (AAT) in a population-based cohort of newly diagnosed nonsmall cell lung cancer (NSCLC) patients. J Clin Oncol 27, 2009 (suppl 15s; abstr 6538)
7. National Cancer Institute: Report of the National Cancer Institute Clinical Trials Program Review Group. http://deainfo.nci.nih.gov/advisory/bsa/bsa-program/ bsactprgmin.pdf
8. Nass SJ, Moses HL, Mendelsohn J (eds): Institute of Medicine. A national cancer clinical trials system for the 21st century: Reinvigorating the NCI Cooperative Group program. Overview of conclusions and recommendations. http://www.nationalacademies. org/hmd/Reports/2010/A-National-Cancer-Clinical-Trials-System-for-the-21st-Century-Reinvigorating-the-NCI-Cooperative.aspx
9. Meropol NJ, Kris MG, Winer EP: The American Society of Clinical Oncology's blueprint for transforming clinical and translational cancer research. J Clin Oncol 30:690-691, 2012.
10. Friends of Cancer Research: Friends Annual Meeting 2016. http://www.focr.org/events/friendsannual-meeting-2016
11. McCoach CE, Berge EM, Lu X, et al: A brief report of the status of central nervous system metastasis enrollment criteria for advanced non-small cell lung cancer clinical trials: A review of the ClinicalTrials.gov trial registry. J Thorac Oncol 11:407-413, 2016
12. Lin NU: Targeted therapies in brain metastases. Curr Treat Options Neurol 16:276, 2014
13. Lin N, Prowell T, Tan A, et al: Modernizing Clinical Trial Eligibility Criteria: Recommendations of the American Society of Clinical Oncology-Friends of Cancer Research Brain Metastases Working Group. J Clin Oncol 35:3760-3773, 2017
14. Chuk MK, Mulugeta Y, Roth-Cline M, et al: Enrolling adolescents in disease/target-appropriate adult oncology clinical trials of investigational agents. Clin Cancer Res 23:9-12, 2017
15. Momper JD, Mulugeta Y, Green DJ, et al: Adolescent dosing and labeling since the Food and Drug Administration Amendments Act of 2007. JAMA Pediatr 167:926-932, 2013
16. Gore L, Ivy P, Balis F, et al: Modernizing clinical trial eligibility: Recommendations of the American Society of Clinical Oncology-Friends of Cancer Research Minimum Age Working Group. J Clin Oncol 35:3781-3787, 2017
17. Samji H, Cescon A, Hogg RS, et al: Closing the gap: Increases in life expectancy among treated HIVpositive individuals in the United States and Canada. PLoS One 8:e81355, 2013
18. Lewden C, Bouteloup V, De Wit S, et al: Allcause mortality in treated HIV-infected adults with CD4 500/mm3 compared with the general population: Evidence from a large European observational cohort collaboration. Int J Epidemiol 41: 433-445, 2012
19. Uldrick TS, Ison G, Rudek MA, et al: Modernizing clinical trial eligibility criteria: Recommendations of the American Society of Clinical Oncology-Friends of Cancer Research HIV Working Group. J Clin Oncol 35:3774-3780, 2017
20. Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents: Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. https://aidsinfo.nih.gov/contentfiles/lvguidelines/ AdultandAdolescentGL.pdf
21. Lichtman SM, Harvey RD, Damiette Smit MA, et al: Modernizing clinical trial eligibility criteria: Recommendations of the American Society of Clinical Oncology-Friends of Cancer Research Organ Dysfunction, Prior or Concurrent Malignancy, and Comorbidities Working Group. J Clin Oncol 35:3753-3759, 2017
22. US Food and Drug Administration: Guidance for industry: Pharmacokinetics in patients with impaired renal function-Study design, data analysis, and impact on dosing and labeling. http://www.fda. gov/downloads/Drugs/Guidances/UCM204959.pdf
23. Criteria Committee of the New York Heart Association: Diseases of the Heart and Blood Vessels: Nomenclature and Criteria for Diagnosis (ed 6). Boston, MA, Little, Brown and Co, 1964
24. Naing A, Veasey-Rodrigues H, Hong DS, et al: Electrocardiograms (ECGs) in phase I anticancer drug development: The MD Anderson Cancer Center experience with 8518 ECGs. Ann Oncol 23:2960-2963, 2012
25. Hurria A, Dale W, Mooney M, et al: Designing therapeutic clinical trials for older and frail adults with cancer: U13 conference recommendations. J Clin Oncol 32:2587-2594, 2014
26. Gerber DE, Laccetti AL, Xuan L, et al: Impact of prior cancer on eligibility for lung cancer clinical trials. J Natl Cancer Inst 106:dju302, 2014
27. Laccetti AL, Pruitt SL, Xuan L, et al: Effect of prior cancer on outcomes in advanced lung cancer: Implications for clinical trial eligibility and accrual. J Natl Cancer Inst 107:djv002, 2015
28. Laccetti AL, Pruitt SL, Xuan L, et al: Prior cancer does not adversely affect survival in locally advanced lung cancer: A national SEER-Medicare analysis. Lung Cancer 98:106-113, 2016
29. Kelly K, Crowley J, Bunn PA Jr, et al: Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non small-cell lung cancer: A Southwest Oncology Group trial. J Clin Oncol 19: 3210-3218, 2001
30. Townsley CA, Selby R, Siu LL: Systematic review of barriers to the recruitment of older patients with cancer onto clinical trials. J Clin Oncol 23: 3112-3124, 2005